CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Sumitomo Pharma Co Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Sumitomo Pharma Co Ltd
2-6-8, Dosho-machi, Chuo-ku
Phone: +81 662035321p:+81 662035321 OSAKA-SHI, OSK  541-0045  Japan Ticker: 45064506
This is a Subsidiary, click here for the Parent Company
Business Summary
Sumitomo Pharma Co Ltd, formerly Sumitomo Dainippon Pharma Co Ltd, is a Japan-based pharmaceutical company. The Company operates its business through four segments. The Japan segment is engaged in the manufacture, purchase, and sale of ethical drugs. The North American segment is engaged in the manufacture, purchase, and sale of ethical drugs and conducts research and development in the areas of oncology, urology, respiratory disease, and regenerative cell medicine. The China segment is engaged in the manufacture (small packaged products) and sale of ethical pharmaceuticals. The Overseas Others segment is engaged in the manufacture and sale of ethical pharmaceuticals in Europe. The segment also purchase and sell ethical pharmaceuticals in Southeast Asia and Taiwan, as well as provide information and collection activities for the Company's products. Other business includes manufacturing, purchasing, and sales of food ingredients, food additives and chemical product materials.
(Source: F-4)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/20243/31/2024Yes----

Industries
SIC Code Description
2833 Medicinal chemicals and botanical products
2834 Pharmaceutical preparations
2869 Industrial organic chemicals, not elsewhere classified
5047 Medical, dental, and hospital equipment and supplies
4225 General warehousing and storage

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
President, Chief Executive Officer, Representative Director ToruKimura 63 6/25/2024 4/1/2015
Executive Vice President, Representative Director MotoyukiSakai 62 6/25/2024 6/25/2024
Managing Executive Officer HiroyukiBaba 63 6/25/2024 4/1/2015
12 additional Officers and Directors records available in full report.

Business Names
Business Name
4506
Boston Biomedical Inc.
Cynapsus Therapeutics Inc.
11 additional Business Names available in full report.

General Information
Number of Employees: 4,980 (As of 3/31/2024)
Outstanding Shares: 397,290,348 (As of 9/30/2024)
Shareholders: 45,437
Stock Exchange: TYO
Fax Number: +81 662026028


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Monday, December 2, 2024